Section R9-6-338. Hepatitis B and Hepatitis D

A.      Case control measures:

1.        A local health agency shall:

a.        Evaluate a health care provider identified as the source of hepatitis B virus transmission in the work place and, if indicated, ensure reassignment of the health care provider to a position where the occupa- tional risk of transmission is eliminated;

b.        Conduct an epidemiologic investigation of each reported case or suspect case of hepatitis B or hepa- titis B co-infected with hepatitis D; and

c.        For each acute case of hepatitis B or hepatitis B co- infected with hepatitis D or case of perinatal hepati- tis B, submit to the Department, as specified in Arti- cle 2, Table 4, the information required under R9-6- 206(D).

2.        The operator of a blood bank, blood center, or plasma center shall notify a donor of a test result with significant evidence  suggestive  of  hepatitis   B,  as  required  under

A.R.S. § 32-1483 and 21 CFR 630.6.

B.       Contact control measures: A local health agency shall:

1.        Refer each non-immune hepatitis B contact to a health care provider for prophylaxis and initiation of the hepati- tis B vaccine series, and

2.        Provide health education related to the progression of hepatitis B disease and the prevention of transmission of hepatitis B infection to each non-immune hepatitis B con- tact.

Historical Note

Renumbered from R9-6-731 and amended effective Octo- ber 19, 1993 (Supp. 93-4). Former Section R9-6-338 renumbered to R9-6-341; new Section R9-6-338 renum- bered from R9-6-335 effective April 4, 1997 (Supp. 97-2).

Former R9-6-338 renumbered to R9-6-346; new R9-6- 338 made by final rulemaking at 10 A.A.R. 3559, effec- tive October 2, 2004 (Supp. 04-3). Former R9-6-338 renumbered to R9-6-340; new R9-6-338 renumbered

from R9-6-336 and amended by final rulemaking at 14

A.A.R. 1502, effective April 1, 2008 (Supp. 08-2).